Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Semin Oncol. 2015 Jun 3;42(4):601–616. doi: 10.1053/j.seminoncol.2015.05.007

Table 2.

Results of Clinical Trials Evaluating the Combination of Cytotoxic Chemotherapy and Ipilimumab in Melanoma and Lung Cancer

Regimen Disease No.
Enrolled		 Response Rate
(%)		 Median PFS
(mo)		 Median OS
(mo)		 Reference
DTIC Melanoma 502 10.3 ~2.8 9.1 34
DTIC plus IPI 15.2 ~2.8 11.2
CT Extensive stage,
SCLC		 130 53 5.3 9.9 36
CT plus IPI 47 5.7 9.1
Phased IPI 71 6.4 12.9
CT NSCLC 204 14 4.2 8.3 35
CT plus IPI 21 4.1 9.7
Phased IPI 32 5.1 12.2
IPI Melanoma 59 33 n/a n/a 33
IPI plus DTIC 33
IPI plus CT 28
Fotemustine
plus IPI		 Melanoma 86 29 5.3 13.3 41
IPI Melanoma 72 5.4 11.4 32
IPI plus DTIC 14.3 14.3

Abbreviations: PFS, progression-free survival; OS, overall survival; DTIC, dacarbazine; IPI, ipilimumab; CT, carboplatin and paclitaxel; SCLC, small cell lung cancer; NSCLC, non-.small cell lung cancer.